|
KineMed announced a broadening of its collaboration with Bristol-Myers Squibb Company in the area of Alzheimer’s disease and other neurodegenerative conditions
EMERYVILLE, CA, USA | February 8, 2010 | KineMed, Inc. a translational and personalized medicine development company, today announced a broadening of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY - News) in the area of Alzheimer’s disease and other neurodegenerative conditions. This agreement builds on the original collaboration between the two companies begun in June 2009.
“We are very pleased to be working with Bristol Myers Squibb to enable the development of their drugs intended to slow the progression of Alzheimer’s disease by novel mechanisms. KineMed is excited by the possibility that our novel measures of brain function could play a crucial role in advancing such potentially beneficial new medicines. The early ability to move forward to human proof of concept studies in the arena of neurodegeneration exemplifies what our Translational Medicine platform can accomplish,” Robert B. Stein, M.D., Ph.D., KineMed’s Chief Executive Officer, said.
About KineMed, Inc.
KineMed, a privately held biotechnology company based in Emeryville, CA, is a leader in translational and personalized medicine. KineMed uses the administration of stable (non-radioactive) isotopes to provide “high-definition” pharmacological measurements of disease activity and drug effects across a wide range of therapy areas, including diseases of the nervous system, metabolic and cardiovascular disease, cancer, inflammation, and musculoskeletal diseases. KineMed is developing a small, high-quality pipeline of its own in-licensed compounds.
SOURCE: KineMed, Inc. |
